- Dr. Benjamin Krantz has assumed the role of CEO at Advanced Proteome Therapeutics’ (APC) US subsidiary, Advanced Proteome Therapeutics Inc.
- Benjamin Krantz MD, MBA was the Chief Fellow in hematology/oncology at New York University Langone Medical Center
- He created investigational protocols for the development of new pancreas cancer biomarkers and an early phase therapeutic candidate
- Dr. Krantz received a BA from the University of Pennsylvania and a Doctor of Medicine and Master of Business Administration from Tufts University
- Advanced Proteome Therapeutics Corp is a biotechnology company
- Advanced Proteome Therapeutics Corporation (APC) is up 15.71 per cent, trading at C$0.405 per share at 11:30 am ET
Dr. Benjamin Krantz has assumed the role of CEO at Advanced Proteome Therapeutics’ (APC) US subsidiary, Advanced Proteome Therapeutics Inc.
Prior to the appointment, Benjamin Krantz MD, MBA was the Chief Fellow in hematology/oncology at New York University Langone Medical Center and served on the Board of Directors of APTI.
His research has resulted in peer-reviewed articles on novel therapeutics for pancreas cancer and emerging biomarkers for therapeutic selection. He has also been the architect of investigational protocols for the development of new pancreas cancer biomarkers and an early phase therapeutic candidate.
Dr. Krantz received a Bachelor of Arts from the University of Pennsylvania and received his Doctor of Medicine and Master of Business Administration from Tufts University.
Following his residency at New York-Presbyterian Hospital, he worked as a hospitalist and clinical/translational researcher at Memorial Sloan Kettering Cancer Center. He is maintaining an academic affiliation at NYU as a Clinical Assistant Professor in the Division of Hematology and Medical Oncology.
Since the announcement of Dr. Krantz’s appointment last December, he has been preparing for this transition. Renowned scientist, Dr. Ravi Chari, has joined the company’s Scientific Advisory Board and Dr. Rajeshkumar Manian has joined as Lead Synthetic Organic Chemist. Furthermore, existing projects with the Zeglis lab continue to advance and APTI has engaged with new potential collaborators.
Dr. Benjamin Krantz, Director and CEO stated,
“I am extremely excited to be taking on the role of CEO at APTI. It is with high conviction for the potential of APTI’s technology and my ability to generate value from it that I have left a promising academic track to lead APTI. APTI is at an exciting crossroads, where we have a developed a platform that continues to demonstrate exciting results with promising novel complementary technologies in the laboratory to generate better antibody-drug conjugates. As a clinical and translational-focused researcher, it is my vision to rapidly move our technologies from the lab to incorporation into prospective therapeutics leading to clinical development. We have certainly received external validation for this approach with the joining of Dr. Chari to our Scientific Advisory Board and Dr. Manian as our Lead Synthetic Organic Chemist, as well as current and potential collaborator interest.
Additionally, we are looking to scale up with new hires and expansion of lab capabilities to accelerate the achievement of key milestones over the next 6 months.
Antibody-drug conjugates continue to be a hot area in biotech where multi-billion-dollar licensing deals for early-stage assets are not uncommon. With our strategy to build wholly-owned clinical candidates using APTI technology, it is my goal to position APTI for that type of success.”
Paul Woodward, CEO of the company stated,
“I’m excited for what the next six months will bring the company. Ben has been brought on board with a singular mandate – commercialize the technology, and he is already rapidly moving down that road. Our near-term goals (within the next 12 months) are to be formally engaged with collaborators, as a precursor to licensing deals, with the longer-term goal of having those partnerships funding proprietary drug development. We believe this to be a logical pathway and the optimal program for driving valuation. In addition to commercialization opportunities, we will continue to develop IP to enhance and add to our current conjugation technologies.”
Advanced Proteome Therapeutics, through its subsidiary, Advanced Proteome Therapeutics Inc., has invented proprietary protein conjugation technology which enables the development of superior antibody-drug conjugates through improved site-specific labelling, drug-antibody ratio control and enabling of combination payloads. Pre-clinical data has demonstrated improved homogeneity and increased in-vivo potency relative to the current state-of-the-art linker technology.
The company believes that the technology will enable the development of safer and more potent antibody-drug conjugate therapeutics and is pursuing licensing and partnership opportunities to advance the development and create shareholder value.
Advanced Proteome Therapeutics Corporation (APC) is up 15.71 per cent, trading at C$0.405 per share at 11:30 am ET.
